What Happened?
New York, NY-based Ovid Therapeutics Appointed Shannon Cincotta as Sr. Director, Talent Acquisition and Management
About the Company
Ovid Therapeutics is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders. Ovid`s drug candidate, OV101, is currently in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies. Ovid has initiated the Phase 2 STARS trial of OV101 in adults with Angelman syndrome and a Phase 1 trial in adolescents with Angelman and Fragile X syndrome to identify doses suitable for younger patients.
About the Person
Shannon Cincotta is Sr. Director, Talent Acquisition and Management at Ovid Therapeutics. Previously, Shannon held various senior HR leadership roles in the industry.
Info Source
News
Short Profile